Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

ATI Inc. manufactures and sells specialty materials and components worldwide. The company operates in two segments: High Performance Materials & Components (HPMC) and Advanced Alloys & Solutions (AA&S). The HPMC segment produces various materials, including titanium and titanium-based alloys, nickel- and cobalt-based alloys and superalloys, advanced powder alloys and other specialty materials, in long product forms, such as ingot, billet, bar, rod, wire, shapes and rectangles, and seamless tubes, as well as precision forgings, components, and machined parts. The segment serves aerospace and defense, medical, and energy markets. The AA&S segment produces zirconium and related alloys, including hafnium and niobium, nickel-based alloys, titanium and titanium-based alloys, and specialty alloys in a variety of forms, such as plate, sheet, and precision rolled strip products. It also provides hot-rolling conversion services, including carbon steel products, and titanium products. This segment offers its solutions to the energy, aerospace and defense, automotive, and electronics markets. The company was formerly known as Allegheny Technologies Incorporated. ATI Inc. was founded in 1960 and is headquartered in Dallas, Texas.

ATI Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

LEROY BALL NAMED LEAD INDEPENDENT DIRECTOR DALLAS, MAY 14, 2026 /PRNEWSWIRE/ -- ATI INC. (NYSE: ATI) ANNOUNCED THAT AT THE CONCLUSION OF ITS 2026 ANNUAL MEETING TODAY, KIMBERLY A. FIELDS BECAME BOARD CHAIR IN ADDITION TO HER ROLE AS CHIEF EXECUTIVE OFFICER AND PRESIDENT.

CEO KIMBERLY A. FIELDS BECOMES ATI BOARD CHAIR

MARGIN EXPANSION AND AEROSPACE DEMAND DRIVE DOUBLE-DIGIT EARNINGS GROWTH GAAP EPS UP 27% YEAR-OVER-YEAR; OPERATING CASH FLOW UP $221 MILLION ADJUSTED EBITDA MARGIN 20.1%, UP 310 BPS. YEAR-OVER-YEAR RAISING FULL YEAR ADJUSTED EARNINGS AND CASH FLOW GUIDANCE  FIRST QUARTER 2026 GAAP FINANCIAL RESULTS SALES OF $1.15 BILLION, UP 1% YEAR-OVER-YEAR, DRIVEN BY A 6% AEROSPACE & DEFENSE INCREASE NET INCOME ATTRIBUTABLE TO ATI OF $118 MILLION, UP 22% YEAR-OVER-YEAR EARNINGS PER SHARE OF $0.85 COMPARED TO $0.67 PER SHARE IN FIRST QUARTER 2025 FIRST QUARTER 2026 NON-GAAP FINANCIAL INFORMATION (A) ADJUSTED NET INCOME ATTRIBUTABLE TO ATI(A) OF $139 MILLION, UP 33% YEAR-OVER-YEAR ADJUSTED EARNINGS PER SHARE(A) OF $1.00, COMPARED TO $0.72 PER SHARE IN FIRST QUARTER 2025 ADJUSTED EBITDA(A) OF $232MILLION, AN INCREASE OF 19% YEAR-OVER-YEAR ADJUSTED EBITDA(A) AS A PERCENTAGE OF SALES OF 20.1%, COMPARED TO 17.0% IN FIRST QUARTER 2025 GUIDANCE THE COMPANY IS PROVIDING SECOND QUARTER AND UPDATED, FULL YEAR 2026 GUIDANCE IN THE TABLE BELOW.

ATI ANNOUNCES FIRST QUARTER 2026 RESULTS

- POSITIVE FULL RESULTS FROM PHASE 1A TRIAL OF ANTI-TSLP/IL-4R BISPECIFIC ANTIBODY ATI-052 EXCEED ACLARIS' TARGET PROFILE, VALIDATING POTENTIAL BEST-IN-CLASS POTENCY ADVANTAGE AND OPPORTUNITY FOR EXTENDED DOSING - - ESTIMATED HALF-LIFE OF APPROXIMATELY 45 DAYS; UNLOCKS OPPORTUNITY FOR UP TO THREE-MONTH DOSING INTERVAL - - COMPLETE AND SUSTAINED INHIBITION OF TSLP-INDUCED AND IL-4 INDUCED CCL17 (TARC) PROVIDES POTENTIAL TO RAISE EFFICACY CEILING IN TH2-DRIVEN DISEASES - - ENROLLMENT AND DOSING ONGOING IN PHASE 1B TRIALS IN ASTHMA AND ATOPIC DERMATITIS (AD) WITH TOP LINE RESULTS EXPECTED IN THE SECOND HALF OF 2026 - - LICHEN PLANUS SELECTED AS LEAD INDICATION FOR ATI-2138; POTENTIAL TO BE FIRST MECHANISTICALLY COMPLETE THERAPEUTIC CANDIDATE DESIGNED TO ADDRESS ROOT INFLAMMATION AND SYMPTOMS - - MANAGEMENT TO HOST A CONFERENCE CALL TO DISCUSS UPDATE TODAY AT 8:30 AM EST - WAYNE, PA., APRIL 28, 2026 (GLOBE NEWSWIRE) -- ACLARIS THERAPEUTICS, INC. (NASDAQ: ACRS), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING NOVEL PRODUCT CANDIDATES FOR IMMUNO-INFLAMMATORY DISEASES, TODAY PROVIDED A CLINICAL UPDATE ON ITS BIOLOGIC AND ORAL INHIBITOR COMPOUNDS INCLUDING POSITIVE FULL TOP LINE RESULTS FROM THE FIRST-IN-HUMAN PHASE 1A SINGLE (SAD) AND MULTIPLE ASCENDING DOSE (MAD) TRIAL OF ITS ANTI-TSLP/IL-4R BISPECIFIC ANTIBODY ATI-052 AND THE SELECTION OF LICHEN PLANUS (LP) AS THE LEAD INDICATION FOR ITS SELECTIVE ITK/JAK3 INHIBITOR ATI-2138.

ACLARIS THERAPEUTICS ANNOUNCES POSITIVE FULL TOP LINE FIRST-IN-HUMAN RESULTS FROM PHASE 1A HEALTHY VOLUNTEER CLINICAL TRIAL OF ATI-052, A NOVEL POTENTIAL FIRST-IN-CLASS ANTI-TSLP/IL-4R BISPECIFIC ANTIBODY, AND ANNOUNCES LICHEN PLANUS AS LEAD INDICATION FOR ATI-2138, AN ORAL ITK/JAK3 INHIBITOR

DALLAS, APRIL 2, 2026 /PRNEWSWIRE/ -- ATI (NYSE: ATI) HAS SCHEDULED THE LIVE WEBCAST FOR ITS FIRST QUARTER 2026 EARNINGS CONFERENCE CALL ON THURSDAY, APRIL 30, 2026,AT7:30 A.M. CT (8:30 A.M.

ATI ANNOUNCES WEBCAST FOR FIRST QUARTER 2026 RESULTS

- PARTICIPANTS WITH ATOPIC DERMATITIS RECEIVING ATI-2138 EXPERIENCED IMPROVEMENTS IN KEY CLINICAL MEASURES INCLUDING DISEASE SEVERITY, ITCH, AND QUALITY OF LIFE - WAYNE, PA., MARCH 27, 2026 (GLOBE NEWSWIRE) -- ACLARIS THERAPEUTICS, INC. (NASDAQ: ACRS), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING NOVEL PRODUCT CANDIDATES FOR IMMUNO-INFLAMMATORY DISEASES, TODAY PROVIDED ADDITIONAL RESULTS FROM ITS PHASE 2A TRIAL OF ATI-2138, A POTENT AND SELECTIVE INVESTIGATIONAL ORAL COVALENT INHIBITOR OF ITK AND JANUS KINASE 3 (JAK3), PRESENTED IN AN ELECTRONIC POSTER AT THE 2026 AMERICAN ACADEMY OF DERMATOLOGY (AAD) ANNUAL MEETING IN DENVER, CO.

RESULTS PRESENTED AT 2026 AMERICAN ACADEMY OF DERMATOLOGY (AAD) ANNUAL MEETING PROVIDE ADDITIONAL SUPPORT FOR THE THERAPEUTIC POTENTIAL OF ATI-2138

WAYNE, PA., MARCH 20, 2026 (GLOBE NEWSWIRE) -- ACLARIS THERAPEUTICS, INC. (NASDAQ: ACRS), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING NOVEL PRODUCT CANDIDATES FOR IMMUNO-INFLAMMATORY DISEASES, TODAY ANNOUNCED THAT AN EPOSTER ON THE RESULTS FROM ITS OPEN-LABEL PHASE 2A TRIAL OF ATI-2138, A POTENT AND SELECTIVE INVESTIGATIONAL ORAL COVALENT INHIBITOR OF INTERLEUKIN-2-INDUCIBLE T CELL KINASE (ITK) AND JANUS KINASE 3 (JAK3), WILL BE AVAILABLE DURING THE 2026 AMERICAN ACADEMY OF DERMATOLOGY (AAD) ANNUAL MEETING IN DENVER, CO. THE POSTER WILL INCLUDE RESULTS NOT PREVIOUSLY REPORTED FROM ACLARIS' PHASE 2A TRIAL IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS (AD).

ACLARIS THERAPEUTICS ANNOUNCES POSTER ON RESULTS FROM PHASE 2A TRIAL OF ATI-2138 AT THE 2026 AMERICAN ACADEMY OF DERMATOLOGY (AAD) ANNUAL MEETING

- TOP LINE RESULTS EXPECTED IN THE FOURTH QUARTER OF 2026 - WAYNE, PA., MARCH 18, 2026 (GLOBE NEWSWIRE) -- ACLARIS THERAPEUTICS, INC. (NASDAQ: ACRS), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING NOVEL PRODUCT CANDIDATES FOR IMMUNO-INFLAMMATORY DISEASES, TODAY ANNOUNCED THAT IT HAS COMPLETED PATIENT ENROLLMENT IN ITS RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 TRIAL OF BOSAKITUG (ATI-045) IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS (AD).

ACLARIS THERAPEUTICS COMPLETES ENROLLMENT IN PHASE 2 TRIAL OF BOSAKITUG (ATI-045) IN ATOPIC DERMATITIS

- POSITIVE INTERIM RESULTS OF PHASE 1A SINGLE (SAD) AND MULTIPLE ASCENDING DOSE (MAD) TRIAL OF ANTI-TSLP/IL-4R BISPECIFIC ANTIBODY ATI-052 SUPPORT RAPID CLINICAL ADVANCEMENT; COMPLETE TOP LINE RESULTS EXPECTED IN THE SECOND QUARTER OF 2026 -  - PHASE 1B PROOF-OF-CONCEPT TRIALS OF ATI-052 IN ATOPIC DERMATITIS (AD) AND ASTHMA UNDERWAY; TOP LINE RESULTS FROM BOTH TRIALS ANTICIPATED IN THE SECOND HALF OF 2026 -  - INVESTIGATIONAL NEW DRUG (IND) APPLICATION FOR LEAD ITK INHIBITOR CANDIDATE ATI-9494 EXPECTED IN THE SECONDHALF OF 2026 -  - ATI-2138, ACLARIS' INVESTIGATIONAL INHIBITOR OF ITK AND JAK3, DEMONSTRATED POTENTIAL BEST-IN-CLASS HAIR REGROWTH IN MURINE ALOPECIA MODEL -  WAYNE, PA., FEB. 26, 2026 (GLOBE NEWSWIRE) -- ACLARIS THERAPEUTICS, INC. (NASDAQ: ACRS), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING NOVEL PRODUCT CANDIDATES FOR IMMUNO-INFLAMMATORY DISEASES, TODAY ANNOUNCED ITS FINANCIAL RESULTS FOR THE FOURTH QUARTER AND FULL YEAR ENDED 2025 AND PROVIDED A CORPORATE UPDATE.

ACLARIS THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

WAYNE, PA., FEB. 24, 2026 (GLOBE NEWSWIRE) -- ACLARIS THERAPEUTICS, INC. (NASDAQ: ACRS), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING NOVEL PRODUCT CANDIDATES FOR IMMUNO-INFLAMMATORY DISEASES, TODAY ANNOUNCED THAT IT HAS INITIATED A PLACEBO-CONTROLLED PHASE 1B PROOF-OF-CONCEPT (POC) TRIAL OF ATI-052, THE COMPANY'S POTENTIAL BEST-IN-CLASS INVESTIGATIONAL BISPECIFIC ANTI-TSLP/IL-4R ANTIBODY, IN ASTHMA. THIS ANNOUNCEMENT FOLLOWS THE RECENT INITIATION OF THE COMPANY'S PHASE 1B POC TRIAL OF ATI-052 IN ATOPIC DERMATITIS (AD).

ACLARIS THERAPEUTICS INITIATES PHASE 1B PROOF-OF-CONCEPT TRIAL IN PATIENTS WITH ASTHMA WITH ITS NOVEL BISPECIFIC ANTI-TSLP/IL-4R ANTIBODY ATI-052

DALLAS, FEB. 19, 2026 /PRNEWSWIRE/ -- ATI INC. (NYSE: ATI) ANNOUNCED THAT ITS BOARD OF DIRECTORS HAS AUTHORIZED THE ADDITIONAL REPURCHASE OF UP TO $500 MILLION OF ITS OUTSTANDING COMMON STOCK, WHICH THE COMPANY CURRENTLY EXPECTS WILL SUPPORT A MULTI-YEAR SHARE REPURCHASE PROGRAM IN COMBINATION WITH THE CURRENTLY REMAINING $120 MILLION FROM ITS PRIOR AUTHORIZATION. REPURCHASES UNDER THE PROGRAM MAY BE MADE IN THE OPEN MARKET OR IN PRIVATELY NEGOTIATED TRANSACTIONS, WITH THE AMOUNT AND TIMING OF REPURCHASES DEPENDING ON MARKET CONDITIONS AND CORPORATE NEEDS.

ATI ANNOUNCES MULTI-YEAR $500 MILLION SHARE REPURCHASE PROGRAM

ANNUAL SALES OF $4.6 BILLION REPRESENT HIGHEST TOTAL SINCE 2012 Q4 2025 SALES OF $1.2 BILLION AND FISCAL YEAR 2025 SALES OF $4.6 BILLION Q4 2025 NET INCOME ATTRIBUTABLE TO ATI OF $97 MILLION, OR $0.69 PER SHARE; FISCAL YEAR 2025 NET INCOME ATTRIBUTABLE TO ATI OF $404 MILLION, OR $2.85 PER SHARE SALES TO THE AEROSPACE & DEFENSE MARKET REPRESENT 68% OF Q4 2025 SALES, UP FROM 65% OF Q4 2024 SALES FISCAL YEAR 2025 OPERATING CASH FLOW OF $614 MILLION, UP FROM $407 MILLION FOR FISCAL YEAR 2024 NON-GAAP INFORMATION(A) Q4 2025 ADJUSTED NET INCOME ATTRIBUTABLE TO ATI(A) OF $130 MILLION, OR $0.93 PER SHARE Q4 2025 ADJUSTED EBITDA(A) OF $232 MILLION, OR 19.7% OF SALES FISCAL YEAR 2025 ADJUSTED FREE CASH FLOW(A) OF $380 MILLION, UP 53% OVER FISCAL YEAR 2024 GUIDANCE THE COMPANY IS PROVIDING FIRST QUARTER AND FISCAL YEAR 2026 GUIDANCE IN THE TABLE BELOW. CURRENT GUIDANCE Q1 2026 FISCAL YEAR 2026 ADJUSTED EBITDA(B) $216M - $226M $975M - $1,025M ADJUSTED EARNINGS PER SHARE(B) $0.83 - $0.89 $3.99 - $4.27 ADJUSTED FREE CASH FLOW(B) $430M - $490M (A) RECONCILIATIONS OF THE REPORTED INFORMATION UNDER ACCOUNTING PRINCIPLES GENERALLY ACCEPTED IN THE UNITED STATES (GAAP) TO NON-GAAP FINANCIAL MEASURES ARE INCLUDED IN ACCOMPANYING FINANCIAL TABLES.

ATI Inc.

ATI

Price

Financial Reports

No items found.

Press Releases

ATI Inc.

ATI.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

ATI